MedTrace Logo

NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy

NCT03194971 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-03-30

No results posted yet for this study

Summary

This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.

Conditions

Interventions

OTHER

Tumor samples from patients treated with TTFields at initial diagnosis.

Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.

DEVICE

Tumor samples from patients treated with TTFields at tumor recurrence.

Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Peter LaViolette, PhD · Medical College of Wisconsin

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2023-06-04
Completion
2023-06-04
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03194971 on ClinicalTrials.gov